Infections, Coronavirus
Conditions
Keywords
COVID-19
Brief summary
The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIb\\IIIa clinical trial.
Detailed description
This is a multicenter prospective, randomized, double-blind, placebo-controlled, parallel-group phase 3 IIb\\IIIa trial to evaluate the efficacy of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). A study will last for 29±3 days (maximum) for each participant and will include: screening (days -1...1); treatment period (17 days in total, days 1...17) with the administration of the investigational product Polyoxidonium/placebo (intravenous injections for 3 days, then intramuscular injections for 14 days), assessment of the clinical status, recording of AEs; follow-up period (days 18...29±3). Haematology and blood chemistry tests will be performed at day -1 and days 1,3, 8 ±1, 17±1. Assessment of the clinical status according to the 7-point ordinal scale and according to the National Early Warning Score (NEWS) scale will be done every day during hospitalization from day 1 up to and including day 17 and at the follow-up on day 29±3. The safety and tolerability will be evaluated throughout the study (from signing the Informed Consent Form to the study completion visit).
Interventions
DRUGazoximer bromide
Investigational medicinal product
OTHERPlacebo
Placebo
Sponsors
NPO Petrovax
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Male and female patients from 18 to 85 years of age. 2. The patient (or his/her legal representative, if the patient is not able to sign the form) signed an Informed Consent form for participation in this study before any initiation of any study procedures. 3. The patient can understand all protocol requirements, perform the study procedures, and agree to all limitations specified in the protocol. 4. Confirmed diagnosis of coronavirus disease (COVID-19): laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen \< 14 days prior to randomization. 5. Illness (coronavirus disease COVID-19) of any duration, and at least one of the following: * Radiographic/tomographic chest infiltrates by imaging (chest x-ray, CT scan, etc.), OR * Evidence of rales/crackles on clinical exam AND SpO2 ≤ 94% on room air, OR * Indications for mechanical ventilation and/or supplemental oxygen. 6. Agrees to use adequate contraception methods (the methods with at least 90% efficacy include non-hormonal intrauterine devices; condom with intravaginal spermicide; cervical caps
Exclusion criteria
1. History of clinically significant allergic reactions. 2. Hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. 3. Anticipated transfer to another hospital which is not a study centre within the next 72 hours. 4. Acute or chronic renal failure. 5. History of HIV infection, tuberculosis. 6. Conditions associated with primary immunodeficiency. 7. Concomitant use of cytostatic medications to treat a concomitant disease. 8. Systemic connective tissue diseases. 9. Need for the prohibited medications. 10. Administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. 11. History of alcohol or drug dependence. 12. History of malignant tumours of any location with remission for less than 2 years. 13. History of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. 14. Pregnancy or breastfeeding. 15. Intravenous injections and/or sampling of the required amount of blood is not possible. 16. Positive pregnancy test (in patients with childbearing potential). 17. Participation in any clinical study within 3 months before enrolment in this study. 18. History of any condition that the study doctor considers significant enough to prevent enrolment of this patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical status of the patient (according to 7-point ordinal scale) | Day 15 | The primary efficacy outcome will be defined based on the blinded analysis of data of the first 100 patients in the 1st part of the study. There is uncertainty about the clinical course and potential different trajectories according to baseline disease severity, so the day of the primary endpoint may be modified based on a blinded evaluation of the primary efficacy outcome in various days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical status of the patient (according to 7-point ordinal scale) | Clinical status of the patient and the average change in the ordinal scale from baseline, both on days 3, 5, 8, 11, 29. | Time to improvement by one category from admission on the ordinal scale. Clinical status of the patient. Average change in the ordinal scale from baseline. |
| NEWS | Change in NEWS from baseline on days 3, 5, 8, 11, 15, 29. | The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first. Change in NEWS from baseline. |
| Oxygenation | Oxygenation free days in the first 28 days (to day 29). Incidence and duration of new oxygen use during the study. | Oxygenation free days. Incidence and duration of new oxygen use. |
| Mechanical Ventilation | Ventilator free days in the first 28 days (to day 29). Incidence and duration of new mechanical ventilation use during the trial. | Ventilator free days. Incidence and duration of new mechanical ventilation use. |
| Mortality | 28-day mortality | — |
Countries
Russia, Slovakia
Outcome results
None listed